| __timestamp | CymaBay Therapeutics, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 59644696 |
| Thursday, January 1, 2015 | 8871000 | 79541000 |
| Friday, January 1, 2016 | 9645000 | 98015000 |
| Sunday, January 1, 2017 | 12387000 | 103958000 |
| Monday, January 1, 2018 | 14381000 | 103654000 |
| Tuesday, January 1, 2019 | 19238000 | 128951000 |
| Wednesday, January 1, 2020 | 17425000 | 135799000 |
| Friday, January 1, 2021 | 23040000 | 149883000 |
| Saturday, January 1, 2022 | 25116000 | 220206000 |
| Sunday, January 1, 2023 | 51953000 | 265542000 |
In pursuit of knowledge
In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, CymaBay Therapeutics, Inc. and Travere Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, CymaBay's SG&A expenses grew by over 500%, peaking in 2023. In contrast, Travere's expenses increased by approximately 345% during the same period, with a notable surge in 2023. This divergence highlights CymaBay's aggressive expansion strategy, while Travere maintains a steady growth path. The data suggests that both companies are investing heavily in operational capabilities, but CymaBay's recent spike could indicate a strategic pivot or increased market competition. Investors and stakeholders should consider these trends when evaluating the companies' future prospects.
Breaking Down SG&A Expenses: Eli Lilly and Company vs CymaBay Therapeutics, Inc.
Novo Nordisk A/S and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: GSK plc vs CymaBay Therapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Insmed Incorporated or Travere Therapeutics, Inc.
BioMarin Pharmaceutical Inc. and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Cytokinetics, Incorporated and CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Ionis Pharmaceuticals, Inc. and CymaBay Therapeutics, Inc.
Alkermes plc or CymaBay Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: CymaBay Therapeutics, Inc. vs Rhythm Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: CymaBay Therapeutics, Inc. vs Veracyte, Inc.
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Soleno Therapeutics, Inc.
CymaBay Therapeutics, Inc. vs Geron Corporation: SG&A Expense Trends